Search Results - Eva Muñoz
- Showing 1 - 20 results of 34
- Go to Next Page
-
1
Terapias de expresión artística a través de la instalación by Eva Muñoz Guinea
Published in Arteterapia (2017-12-01)Get full text
Article -
2
-
3
Use of Principal Component Analysis to Combine Genetic Merit for Heat Stress and for Fat and Protein Yield in Spanish Autochthonous Dairy Goat Breeds by Alberto Menéndez-Buxadera, Eva Muñoz-Mejías, Manuel Sánchez, Juan Manuel Serradilla, Antonio Molina
Published in Animals (2021-03-01)Get full text
Article -
4
La estereotipia social de los adolescentes italianos durante la práctica deportiva (The social stereotype of Italian adolescents during sports practice) by Eva Muñoz Jiménez, Daniel Garrote Rojas, Cristina Sánchez Romero, Stefano Martelli, Giovanna Russo
Published in Retos: Nuevas Tendencias en Educación Física, Deportes y Recreación (2021-01-01)Get full text
Article -
5
-
6
Selection Criteria for Improving Fertility in Spanish Goat Breeds: Estimation of Genetic Parameters and Designing Selection Indices for Optimal Genetic Responses by Chiraz Ziadi, Eva Muñoz-Mejías, Manuel Sánchez, María Dolores López, Olga González-Casquet, Antonio Molina
Published in Animals (2021-02-01)Get full text
Article -
7
Genetic analysis of litter size and number of kids born alive across parities in Spanish goat breeds using a random regression model by Chiraz Ziadi, Eva Muñoz-Mejías, Manuel Sánchez Rodríguez, María Dolores López, Olga González-Casquet, Antonio Molina Alcalá
Published in Italian Journal of Animal Science (2021-01-01)Get full text
Article -
8
-
9
Living labs for migrant health research: the challenge of cocreating research with migrant population and policy makers by Mònica Ubalde-Lopez, Ana Requena-Mendez, Eva Muñoz, Stella Evangelidou, Laura Giménez, María Jesús Pinazo, Anne-Sophie Gresle, Leonardo de la Torre, Oriol Recasens
Published in BMJ Global Health (2024-08-01)Get full text
Article -
10
Evidence of Active Pro-Fibrotic Response in Blood of Patients with Cirrhosis. by Gloria Sanchez-Antolín, Carolina Almohalla-Alvarez, Pilar Bueno, Raquel Almansa, Verónica Iglesias, Lucia Rico, Alicia Ortega, Eva Muñoz-Conejero, Felix García-Pajares, Jesus F Bermejo-Martin
Published in PLoS ONE (2015-01-01)Get full text
Article -
11
Incidence and characteristics of adverse drug reactions in a cohort of patients treated with PD-1/PD-L1 inhibitors in real-world practice by Mònica Sabaté Gallego, Mònica Sabaté Gallego, Eulàlia Pérez Esquirol, Núria Garcia Doladé, Xavier Vidal Guitart, Xavier Vidal Guitart, Maria-Josep Carreras Soler, Anna Farriols Danés, Enriqueta Felip, Enriqueta Felip, Irene Braña, Irene Braña, Joan Carles Galceran, Joan Carles Galceran, Rafael Morales Barrera, Rafael Morales Barrera, Eva Muñoz-Couselo, Eva Muñoz-Couselo, Antònia Agustí Escasany, Antònia Agustí Escasany
Published in Frontiers in Medicine (2022-08-01)Get full text
Article -
12
Complete response of metastatic cutaneous squamous cell carcinoma and multiple locally advanced basal cell carcinomas with concomitant pembrolizumab and sonidegib therapy by Carlos González-Cruz, MD, Eva Muñoz-Couselo, MD, PhD, Carolina Ortiz-Velez, MD, Berta Ferrer, MD, Vicente García-Patos, MD, PhD, Carla Ferrándiz-Pulido, MD, PhD
Published in JAAD Case Reports (2024-04-01)Get full text
Article -
13
Loss of Lkb1 cooperates with BrafV600E and ultraviolet radiation, increasing melanoma multiplicity and neural‐like dedifferentiation by Kimberley McGrail, Elena González‐Sánchez, Paula Granado‐Martínez, Roberto Orsenigo, Yuxin Ding, Berta Ferrer, Javier Hernández‐Losa, Iván Ortega, Juan Martín‐Caballero, Eva Muñoz‐Couselo, Vicente García‐Patos, Juan A. Recio
Published in Molecular Oncology (2025-02-01)Get full text
Article -
14
Association between toothbrushing and cardiovascular risk factors: a cross-sectional study using Korean National Health and Nutrition Examination Survey 2015–2017 by Mi-Gil Moon, Si-Hyuck Kang, Sun-Hwa Kim, Shin-Young Park, Yang-Jo Seol, Chang-Hwan Yoon, Hyo-Jung Lee, Tae-Jin Youn, In-Ho Chae, Yago Leira, Eva Munoz-Aguilera, Francesco D’Aiuto
Published in BMC Oral Health (2024-01-01)Get full text
Article -
15
338 Effects of pembrolizumab on the tumor microenvironment (TME) after one presurgery treatment cycle in patients with triple-negative breast cancer (TNBC): phase 1b KEYNOTE-173 st... by Sung-Bae Kim, Jennifer Yearley, Rebecca Dent, Javier Cortes, Lingkang Huang, Yeon Hee Park, Theodoros Foukakis, Eva Muñoz-Couselo, Yuan Sun, Peter Schmid, Joohyuk Sohn, Seock-Ah Im, Esther Holgado, Sherko Kümmel, Petar Jelinic, Vassiliki Karantza
Published in Journal for ImmunoTherapy of Cancer (2021-11-01)Article -
16
Irvalec inserts into the plasma membrane causing rapid loss of integrity and necrotic cell death in tumor cells. by José M Molina-Guijarro, Álvaro Macías, Carolina García, Eva Muñoz, Luis F García-Fernández, Miren David, Lucía Núñez, Juan F Martínez-Leal, Victoria Moneo, Carmen Cuevas, M Pilar Lillo, Carlos Villalobos Jorge, Carmen Valenzuela, Carlos M Galmarini
Published in PLoS ONE (2011-04-01)Get full text
Article -
17
Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of th... by Rebecca Dent, Javier Cortés, Yeon Hee Park, Eva Muñoz-Couselo, Sung-Bae Kim, Joohyuk Sohn, Seock-Ah Im, Esther Holgado, Theodoros Foukakis, Sherko Kümmel, Jennifer Yearley, Anran Wang, Michael Nebozhyn, Lingkang Huang, Razvan Cristescu, Petar Jelinic, Vassiliki Karantza, Peter Schmid
Published in Breast Cancer Research (2025-03-01)Get full text
Article -
18
Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study. by Graham Cohen, Bernardo Rapoport, Sze W Chan, Paul Ruff, Ana Arance, Karmele Mujika Eizmendi, Baerin Houghton, Michael P Brown, Robert M Zielinski, Eva Muñoz Couselo, Megan Lyle, James R Anderson, Lokesh Jain, Dinesh de Alwis, Mallika Lala, Omobolaji Akala, Elliot Chartash, Conrad Jacobs
Published in PLoS ONE (2024-01-01)Get full text
Article -
19
Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study by Graham Cohen, Bernardo Rapoport, Sze W. Chan, Paul Ruff, Ana Arance, Karmele Mujika Eizmendi, Baerin Houghton, Michael P. Brown, Robert M. Zielinski, Eva Muñoz Couselo, Megan Lyle, James R. Anderson, Lokesh Jain, Dinesh de Alwis, Mallika Lala, Omobolaji Akala, Elliot Chartash, Conrad Jacobs
Published in PLoS ONE (2024-01-01)Get full text
Article -
20
Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629 by Åse Bratland, Eva Munoz-Couselo, Laurent Mortier, Osama Roshdy, Rene González, Jacob Schachter, Ana M. Arance, Florent Grange, Nicolas Meyer, Abhishek Jagdish Joshi, Salem Billan, Brett G. M. Hughes, Jean-Jacques Grob, Karthik Ramakrishnan, Joy Ge, Burak Gumuscu, Ramona F. Swaby, Ralf Gutzmer
Published in Dermatology and Therapy (2023-11-01)Get full text
Article
